Colorectal Tumors Found to Leverage Mitochondrial Complex II for Iron Storage

Colorectal cancer tumors rely on mitochondrial complex II to stockpile iron for survival, according to research reported by Medical Xpress on June 17, 2026. Researchers found that eliminating this specific mitochondrial complex triggers ferroptosis, a form of iron-dependent cell death, which provides a potential new target for oncological therapies.

The findings identify a metabolic vulnerability in colorectal tumors. While mitochondrial complex II typically functions within the electron transport chain to produce energy, these tumors repurpose the complex to manage iron levels. According to the report, this iron accumulation is essential for the tumor’s continued growth and proliferation.

When scientists blocked or removed mitochondrial complex II, the tumor cells couldn’t maintain their iron balance. This disruption led to the rapid accumulation of lethal lipid peroxides, causing the cells to collapse and die. The researchers identified this process as ferroptosis, a regulated cell death mechanism distinct from apoptosis.

How does mitochondrial complex II help tumors grow?

Mitochondrial complex II, also known as succinate dehydrogenase, plays a dual role in the cell by participating in both the citric acid cycle and the mitochondrial respiratory chain. In colorectal cancer cells, this complex acts as a hub for iron storage. According to the Medical Xpress report, the tumors use this mechanism to ensure a steady supply of iron, which is a critical cofactor for various enzymes needed for DNA synthesis and energy production.

The stockpiling isn’t just about availability; it’s about stability. By sequestering iron via complex II, the tumor prevents the metal from reacting prematurely with oxygen and lipids, which would otherwise damage the cell. This allows the cancer to maintain high iron levels without suffering the toxic effects usually associated with iron overload.

This metabolic adaptation gives colorectal tumors a competitive advantage over healthy cells. It allows them to thrive in nutrient-poor environments and resist certain types of cellular stress that would normally trigger death.

What happens when mitochondrial complex II is eliminated?

Eliminating mitochondrial complex II removes the tumor’s ability to safely store iron. According to the research, this removal triggers a catastrophic failure in the cell’s antioxidant defenses. Specifically, the iron that was once safely stockpiled becomes “labile” or chemically active.

This free iron reacts with hydrogen peroxide in a process known as the Fenton reaction. This reaction generates highly reactive hydroxyl radicals that attack the polyunsaturated fatty acids in the cell membrane. The result is lipid peroxidation, where the cell’s outer membrane essentially rusts from the inside out.

The researchers noted that this specific sequence of events leads to ferroptosis. Unlike apoptosis, which is a programmed “suicide” where the cell shrinks and is absorbed, ferroptosis involves the rupture of the cell membrane and the release of intracellular contents, effectively killing the tumor cell.

Why is this different from traditional cancer treatments?

Most conventional chemotherapies target rapidly dividing cells by damaging DNA or interfering with mitosis. This approach often affects healthy cells, leading to systemic toxicity. The targeting of mitochondrial complex II represents a shift toward metabolic therapy. It focuses on the unique biochemical requirements of the tumor rather than just its growth rate.

Comparing this approach to traditional methods reveals a few distinct differences:

• Mechanism: Traditional chemo targets DNA; this method targets iron metabolism and lipid stability.
• Cell Death Path: Traditional chemo primarily induces apoptosis; this method induces ferroptosis.
• Specificity: Because healthy cells may not rely on complex II for iron stockpiling in the same way tumors do, this approach could potentially reduce off-target damage.

The research suggests that because colorectal tumors are particularly dependent on this iron-stockpiling mechanism, they are more susceptible to complex II inhibition than non-cancerous tissues.

What are the next steps for this research?

While the discovery of the complex II-iron link provides a clear target, the researchers must now determine how to inhibit this complex safely in a clinical setting. The challenge lies in developing a drug that can selectively disable mitochondrial complex II in tumor cells without disrupting the energy production of vital organs, such as the heart or brain.

According to the report, future studies will likely focus on identifying small-molecule inhibitors that can penetrate the mitochondrial membrane. Researchers also intend to investigate whether this vulnerability exists in other types of gastrointestinal cancers or if it is unique to colorectal tumors.

The findings suggest that monitoring iron levels and mitochondrial complex II expression could eventually serve as a biomarker to predict which patients would respond best to ferroptosis-inducing therapies.